Inactive Instrument

News Corcept Therapeutics Nasdaq

Equities

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)	Apr. 15	GL
Corcept Completes Enrollment in Phase 2 Dazals Trial in Patients with Amyotrophic Lateral Sclerosis	Apr. 15	CI
Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer	Apr. 08	GL
Corcept Therapeutics Incorporated Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer	Apr. 08	CI
Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome	Apr. 01	GL
Corcept Therapeutics Incorporated Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients with Adrenal Cushing's Syndrome	Apr. 01	CI
Corcept Therapeutics Insider Sold Shares Worth $430,475, According to a Recent SEC Filing	Mar. 21	MT
Sector Update: Health Care Stocks Advance Friday Afternoon	Feb. 16	MT
Truist Securities Adjusts Price Target on Corcept Therapeutics to $42 From $36, Maintains Buy Rating	Feb. 16	MT
Sector Update: Health Care Stocks Gain Pre-Bell Friday	Feb. 16	MT
Corcept Therapeutics Q4 Net Income, Revenue Increase; Reiterates Guidance; Shares Gain Pre-Bell	Feb. 16	MT
Sector Update: Health Care	Feb. 16	MT
Corcept Therapeutics Q4 Net Income, Revenue Increase; Reiterates Guidance	Feb. 15	MT
Corcept Therapeutics Incorporated Provides Revenue Guidance for the Year 2024	Feb. 15	CI
Transcript : Corcept Therapeutics Incorporated, Q4 2023 Earnings Call, Feb 15, 2024	Feb. 15
Corcept: Q4 Earnings Snapshot	Feb. 15	AQ
Corcept Therapeutics Incorporated Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15	CI
Corcept Therapeutics Incorporated Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 15	CI
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update	Feb. 15	GL
Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial	Feb. 15	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Corcept Therapeutics Nasdaq

Equities

Summary

Filters